# Shionogi

Targeted therapies — Off-target mitigation.

Source: https://en.bioecon.ru/companies/shionogi/
Updated: 2026-07-02

- Country: Japan

## Verifiable facts

| Fact | Value | Source |
| --- | --- | --- |
| Funding | $482 million contract from U.S. government (Project BioShield) for domestic manufacturing of Fetroja | https://www.pharmexec.com/view/shionogi-inc-awarded-482-million-contract-us-government-enhance-national-preparedness-drug-resistant-bacterial-threats |
| Revenue | 438.3 billion yen for fiscal year 2024 | https://www.shionogi.com/content/dam/shionogi/global/investors/ir-library/annual-report-integrated-report/pdf/ir2025/Shionogi25E_78_96.pdf, https://www.shionogi.com/content/dam/shionogi/global/investors/ir-library/annual-securities-report/Annual%20Securities%20Report%20159th.pdf |
| Headcount | 5,485 employees (global consolidation) as of March 31, 2024 | https://www.shionogi.com/content/dam/shionogi/global/investors/ir-library/annual-report-integrated-report/pdf/ir2025/Shionogi25E_78_96.pdf, https://www.shionogi.com/content/dam/shionogi/global/investors/ir-library/annual-securities-report/Annual%20Securities%20Report%20159th.pdf, https://www.shionogi.com/global/en/sustainability/data.html |
| Production site | Amagasaki, Tokushima, and Kanegasaki (Shionogi Pharma) | https://www.shionogi-ph.co.jp/en/introduction/bulk_drug.html |
| Capacity | Production units ranging from desk-top (0.2kg/hr) to commercial size (5kg/hr) and medium/large manufacturing (>500kg) | https://www.shionogi-ph.co.jp/en/introduction/bulk_drug.html, https://www.shionogi.com/content/dam/shionogi/global/investors/ir-library/annual-report-integrated-report/pdf/ir2025/Shionogi25E_32_56.pdf |

Independent sources: pharmexec.com

## Technologies

- [Anti-AMR antibiotics](https://en.bioecon.ru/technology/antibiotics-new-gen-anti-amr/)